Senetek PLC Announces Status of Annual General Meeting and Status of Voting on Shareholder Resolutions
As of November 12, proxies representing approximately 99.4% of theCompany's voting have been received by the Company. The following tablesummarizes the voting results to date for each resolution to be considered atthe rescheduled Annual General Meeting. Please note that proxy votinginstructions may be withdrawn or changed prior to the rescheduled AnnualGeneral Meeting and, as result, the following information may not beindicative of the actual final vote tallies that will be reported followingthe conclusion of the rescheduled Annual General Meeting:
Due to a technical error in proxy solicitation, approximately 200 Ordinaryshareholders holding approximately 300,000 shares did not receive notice ofthe meeting, proxy cards or the proxy statement in relation to the meetings.A revised notice, along with proxy cards and the proxy statement are beingsent to these holders of Ordinary shares. Holders who had previously receivedthe notice of meeting and related proxy materials will receive a revisednotice of meeting. All votes received by the dates provided in the revisednotice of meeting will be tabulated and included in the final vote to bepublished after the Annual General Meeting on December 10, 2007.
About Senetek PLC
Senetek PLC (OTCBB: SNTKY) is a specialty life sciences company engaged inthe study of senescense, the science of aging with an initial focus onskincare and dermatological therapeutics. Senetek recently announced aMarketing Collaboration Agreement for its second-generation cytokinin withTriax Aesthetics LLC which will guarantee a minimum of $10.8 million inrevenues in 2008 and granted Valeant Pharmaceuticals a paid up license forSenetek's first generation patented skin care active ingredient Kinetin andits analog Zeatin in return for $21 million cash and forgiveness of $6 millionprepaid royalty credit, and is negotiating third party license agreements fornew patent-pending second generation dermatological active ingredients and iscompleting development of a number of additional compounds. In addition,Senetek has entered into exclusive licenses for Europe and North America,respectively, for Invicorp(R), has an exclusive manufacturing distributorshipfor its proprietary diagnostic monoclonal antibodies, and recently sold, withretained rights of profit participation, its patented drug delivery system,Reliaject(R). For more information, visit the company's website athttp://www.senetekplc.com.
This news release contains statements that may be considered'forward-looking statements' within the meaning of the Private SecuritiesLitigation Reform Act. Forward-looking statements by their nature involvesubstantial uncertainty, and actual results may differ materially from thosethat might be suggested by such statements. Important factors identified bythe Company that it believes could result in such material differences aredescribed in the Company's Annual Report on Form 10-K for the year 2006.However, the Company necessarily can give no assurance that it has identifiedor will identify all of the factors that may result in any particularforward-looking statem
You May Also Like